Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Deferred Revenue: 2018-2025

Historic Current Deferred Revenue for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $58,627.

  • China SXT Pharmaceuticals' Current Deferred Revenue rose 295.81% to $5,240 in Q3 2025 from the same period last year, while for Sep 2025 it was $5,240, marking a year-over-year increase of 295.81%. This contributed to the annual value of $58,627 for FY2025, which is 68.76% down from last year.
  • China SXT Pharmaceuticals' Current Deferred Revenue amounted to $58,627 in FY2025, which was down 68.76% from $187,665 recorded in FY2024.
  • China SXT Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $257,449 during FY2021, with a 5-year trough of $58,627 in FY2025.
  • Over the past 3 years, China SXT Pharmaceuticals' median Current Deferred Revenue value was $165,534 (recorded in 2023), while the average stood at $137,275.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Current Deferred Revenue tumbled by 69.95% in 2022 and then soared by 113.96% in 2023.
  • Over the past 5 years, China SXT Pharmaceuticals' Current Deferred Revenue (MRY) stood at $257,449 in 2021, then tumbled by 69.95% to $77,366 in 2022, then skyrocketed by 113.96% to $165,534 in 2023, then rose by 13.37% to $187,665 in 2024, then tumbled by 68.76% to $58,627 in 2025.
  • Its Current Deferred Revenue was $58,627 in FY2025, compared to $187,665 in FY2024 and $165,534 in FY2023.